The stock price of Amicus Therapeutics Inc (NASDAQ: FOLD) has plunged by -1.64 when compared to previous closing price of 6.08, but the company has seen a -10.34% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-07 that PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m.
Is It Worth Investing in Amicus Therapeutics Inc (NASDAQ: FOLD) Right Now?
The 36-month beta value for FOLD is also noteworthy at 0.62. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for FOLD is 297.53M, and at present, short sellers hold a 6.18% of that float. The average trading volume of FOLD on May 12, 2025 was 3.58M shares.
FOLD’s Market Performance
The stock of Amicus Therapeutics Inc (FOLD) has seen a -10.34% decrease in the past week, with a -13.21% drop in the past month, and a -38.03% fall in the past quarter. The volatility ratio for the week is 5.87%, and the volatility levels for the past 30 days are at 4.91% for FOLD. The simple moving average for the past 20 days is -11.87% for FOLD’s stock, with a -38.57% simple moving average for the past 200 days.
Analysts’ Opinion of FOLD
Many brokerage firms have already submitted their reports for FOLD stocks, with Morgan Stanley repeating the rating for FOLD by listing it as a “Equal-Weight.” The predicted price for FOLD in the upcoming period, according to Morgan Stanley is $12 based on the research report published on December 13, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $18. The rating they have provided for FOLD stocks is “Buy” according to the report published on September 06th, 2024.
Wells Fargo gave a rating of “Overweight” to FOLD, setting the target price at $18 in the report published on May 30th of the previous year.
FOLD Trading at -23.27% from the 50-Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.73% of loss for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -8.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.93% lower at present.
During the last 5 trading sessions, FOLD fell by -10.34%, which changed the moving average for the period of 200-days by -42.00% in comparison to the 20-day moving average, which settled at $6.79. In addition, Amicus Therapeutics Inc saw -36.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FOLD starting from Campbell Bradley L, who sale 400 shares at the price of $10.00 back on Feb 19 ’25. After this action, Campbell Bradley L now owns 1,150,657 shares of Amicus Therapeutics Inc, valued at $4,000 using the latest closing price.
BRADLEY CAMPBELL, the Director of Amicus Therapeutics Inc, proposed sale 400 shares at $9.85 during a trade that took place back on Feb 19 ’25, which means that BRADLEY CAMPBELL is holding shares at $3,940 based on the most recent closing price.
Stock Fundamentals for FOLD
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.91 for the gross margin
The net margin for Amicus Therapeutics Inc stands at -0.05. The total capital return value is set at 0.06. Equity return is now at value -18.12, with -3.89 for asset returns.
Based on Amicus Therapeutics Inc (FOLD), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at 0.01. The debt to equity ratio resting at 2.29. The interest coverage ratio of the stock is 0.79.
Currently, EBITDA for the company is 29.39 million with net debt to EBITDA at 4.88. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In summary, Amicus Therapeutics Inc (FOLD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
